【摘要】 目的 探讨肝动脉介入化疗栓塞术治疗肝癌的疗效和安全性。方法 收集2016年3月至2021年7月于首都医科大学附属北京友谊医院平谷医院就诊的143例肝癌患者的临床资料，按照治疗方法的不同将其分为栓塞组（n=82，采用肝动脉介入化疗栓塞术治疗）和对照组（n=61，采用肝动脉化疗灌注术治疗）。随访1年后，比较两组患者随访期间的生存情况、缓解情况及不良反应发生情况。结果 随访1年后，栓塞组患者病死率为9.8%(8/82)，低于对照组患者的23.0%(14/61)，差异有统计学意义（P﹤0.05）。栓塞组患者总缓解率为74.4%(61/82)，与对照组患者的63.9%(39/61)比较，差异无统计学意义（P﹥0.05）。栓塞组患者不良反应总发生率为29.3%(24/82)，与对照组患者的27.9%(17/61)比较，差异无统计学意义（P﹥0.05）。结论 肝动脉介入化疗栓塞术治疗肝癌的疗效较好，安全性较高，值得在临床上推广应用。更多还原

【Abstract】 Objective To analyze the efficacy and safety of transarterial chemoembolization in the treatment of liver cancer. Method Clinical data of 143 patients with liver cancer treated in the Pinggu Hospital, Beijing Friendship Hospital, Capital Medical University from March 2016 to July 2021 were selected, they were divided into the embolization group(n=82, treated with transarterial chemoembolization) and control group(n=61, treated with chemotherapy perfusion) according to the different treatment methods. The survival, remission condition and adverse reactions during 1 year of follow up were compared. Result After 1 year of follow up, the mortality in the embolization group was 9.8%(8/82) lower than that in the control group 23.0%(14/61), the difference was statistically significant(P<0.05). There was no significant difference for the overall remission rate in two groups [74.4%(61/82) vs 63.9%(39/61), P>0.05]. There was no significant difference for the incidence of adverse reaction in two groups [29.3%(24/82) vs 27.9%(17/61), P>0.05]. Conclusion Transarterial chemoembolization is effective and safe in the treatment of liver cancer, it is worth promoting and applying in clinical practice.更多还原